AIM Vaccine (HKG:6660) said the results of the phase 3 clinical trial of its iterative serum-free rabies vaccine showed the product has good immunogenicity and safety
Compared with other rabies vaccines, the company's vaccine does not contain animal serum and therefore has a reduced probability of causing any adverse reaction making it a safer option globally, the disclosure said.
The top Chinese full-chain vaccine corporation's shares surged nearly 15% in recent trade.
Price (HKD): $12.40, Change: $+1.6, Percent Change: +14.81%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。